Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PHP1003 in moderate to severe thyroid eye disease in China
ChiCTR2400092189Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of KHN939 in Graves Orbitopathy (GO) (3 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoints: Exophthalmos response rate of the study eye and Mass cytometry. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
KHN939
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2400092189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092189.